Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes

Show simple item record

dc.contributor.author Januszewski, Andrzej S.
dc.contributor.author Chen, David
dc.contributor.author Scott, Russell S.
dc.contributor.author O'Connell, Rachel L.
dc.contributor.author Aryal, Nanda R.
dc.contributor.author Sullivan, David R.
dc.contributor.author Watts, Gerald F.
dc.contributor.author Taskinen, Marja-Riitta
dc.contributor.author Barter, Philip J.
dc.contributor.author Best, James D.
dc.contributor.author Simes, R. John
dc.contributor.author Keech, Anthony C.
dc.contributor.author Jenkins, Alicia J.
dc.date.accessioned 2021-11-02T06:29:03Z
dc.date.available 2021-11-02T06:29:03Z
dc.date.issued 2021-09-21
dc.identifier.citation Januszewski , A S , Chen , D , Scott , R S , O'Connell , R L , Aryal , N R , Sullivan , D R , Watts , G F , Taskinen , M-R , Barter , P J , Best , J D , Simes , R J , Keech , A C & Jenkins , A J 2021 , ' Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes ' , Scientific Reports , vol. 11 , no. 1 , 18708 . https://doi.org/10.1038/s41598-021-98064-y
dc.identifier.other PURE: 169990030
dc.identifier.other PURE UUID: fb17551e-7e2c-4a88-8d58-5824c49af7c0
dc.identifier.other WOS: 000697793400049
dc.identifier.other ORCID: /0000-0002-6229-3588/work/102515309
dc.identifier.uri http://hdl.handle.net/10138/335939
dc.description.abstract People with diabetes are at risk of chronic complications and novel biomarkers, such as Advanced glycation end-products (AGEs) may help stratify this risk. We assessed whether plasma low-molecular weight AGEs, also known as LMW-fluorophores (LMW-F), are associated with risk factors, predict complications, and are altered by fenofibrate in adults with type 2 diabetes. Plasma LMW-F were quantified at baseline, after six weeks fenofibrate, and one year post-randomisation to fenofibrate or placebo. LMW-F associations with existing and new composite vascular complications were determined, and effects of fenofibrate assessed. LMW-F correlated positively with age, glycated haemoglobin (HbA1c), pulse pressure, kidney dysfunction and inflammation; and negatively with urate, body mass index, oxidative stress and leptin, albeit weakly (r = 0.04-0.16, all p < 0.01). Independent determinants of LMW-F included smoking, diastolic blood pressure, prior cardiovascular disease or microvascular complications, Caucasian ethnicity, kidney function, HbA1c and diabetes duration (all p en
dc.format.extent 12
dc.language.iso eng
dc.relation.ispartof Scientific Reports
dc.rights cc_by
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject GLYCATION END-PRODUCTS
dc.subject AGE-PEPTIDES
dc.subject FLUORESCENCE
dc.subject SERUM
dc.subject ACCUMULATION
dc.subject ENDPRODUCTS
dc.subject RETINOPATHY
dc.subject MELLITUS
dc.subject EVENTS
dc.subject PEOPLE
dc.subject 3121 General medicine, internal medicine and other clinical medicine
dc.title Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes en
dc.type Article
dc.contributor.organization Clinicum
dc.contributor.organization Marja-Riitta Taskinen Research Group
dc.contributor.organization HUS Heart and Lung Center
dc.contributor.organization Department of Medicine
dc.contributor.organization CAMM - Research Program for Clinical and Molecular Metabolism
dc.contributor.organization Research Programs Unit
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1038/s41598-021-98064-y
dc.relation.issn 2045-2322
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
s41598_021_98064_y.pdf 1.799Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record